Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14147
UPID:
DHX34_HUMAN
Alternative names:
DEAH box protein 34; DExH-box helicase 34
Alternative UPACC:
Q14147; B4DMY8
Background:
The Probable ATP-dependent RNA helicase DHX34, also known as DEAH box protein 34 and DExH-box helicase 34, plays a crucial role in the nonsense-mediated decay (NMD) pathway. It is essential for the degradation of mRNA transcripts that contain premature stop codons. DHX34 enhances the phosphorylation of UPF1 and facilitates its interaction with UPF2 and EIF4A3, key proteins in the NMD pathway. Additionally, it interacts with the RUVBL1-RUVBL2 complex, influencing its nucleotide binding and ATP hydrolysis capabilities.
Therapeutic significance:
Understanding the role of Probable ATP-dependent RNA helicase DHX34 could open doors to potential therapeutic strategies.